Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Advanced Micro Devices

ARK Innovation ETF

Broadcom

Advanced Micro Devices, Broadcom, the ARKK ETF and Zoetis were our top stock trades for Wednesday. Now, let's take a look at the charts.

4 Top Stock Trades for Wednesday: AVGO, AMD, ARKK, ZTS

Altice USA

British American Tobacco

Charter Communications

Comcast

Mastercard

Otis Worldwide

PayPal

Raytheon Technologies

Visa

Tobacco stocks remain strong buys after the defeat of the U.S. "nicotine tax" proposal and a reassuring update from British American Tobacco. In Payment, Mastercard and Visa each rebounded by more than 10%; U.S. holiday retail sales were strong and credit cards kept growing.

Librarian Capital's Monthly Top Buys And Price Moves - January 2022

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #JPM22--Zoetis will participate in the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10, 2022.

Zoetis to Participate in the 40th Annual J.P. Morgan Healthcare Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis will report Q4 and full year 2021 financial results on Tuesday, Feb. 15, 2022.

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2021 Financial Results

AbbVie

Abbott Labs

Alexandria Real Estate Equities

C.H. Robinson Worldwide

Edison

Enbridge

Erie Indemnity

Hooker Furniture

Mid-America Apartment Communities

Pfizer

SPDR S&P 500 ETF Trust

Stryker

Hanover Insurance Group

Trinity Industries

Union Pacific

W. P. Carey

In this article series, we provide a weekly summary of dividend changes. A summary table provides relevant data and key statistics of dividend increases.

Dividend Increases: December 4-10, 2021

CVS Health

Johnson Controls

Pentair

Zoetis, Pentair, Johnson Controls International, and Abbott Laboratories were among the many companies that declared dividend increases this week.

CVS, Abbot, and Other Companies That Raised Their Dividends This Week

Zoetis, CVS Health, and Other Companies That Raised Their Dividends

The board of directors of Zoetis Inc (NYSE: ZTS) has approved a $3.5 billion share repurchase program. The company added that the new share buyback, spanning across a multi-year period, could be canceled at any time.

Zoetis Raises FY22 Dividend By 30%, Announces New Buyback Program Of $3.5B

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced a $3.5 billion share repurchase program and declared its first quarter 2022 dividend.

Zoetis Announces Authorization of $3.5 Billion Share Repurchase Program

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DriventoCare--Zoetis has been named to Newsweek Magazine's America's Most Responsible Companies 2022 list.

Zoetis Named One of Newsweek's Most Responsible Companies for 2022

CNH Industrial NV

DexCom

Zebra Technologies

When a company's return on equity (ROE) ratio is better than most of its competitors, it generally indicates that the company has been very efficient in generating profits. Thus, investors may want to consider the following stocks, as they are performing better than most of their peer group companies in terms of a higher ROE ratio.

4 Large-Cap Stocks With High Returns on Equity

JOHANNESBURG--(BUSINESS WIRE)-- #SouthAfrica--Zoetis, an affiliate of the global animal health company, has been officially recognized as one of the best places to work in South Africa for 2021. Employees ranked the company favorably in all the eight workplace factors of the certification – more than 88% of employees said the company is offering a great atmosphere and provides challenging work, and 99% of employees are recommending the organization, 17 points higher compared to a typical South African company

Zoetis Awarded the Best Place To Work Certification in South Africa for 2021

Zoetis Inc. (ZTS) CEO Kristin Peck on Q3 2021 Results - Earnings Call Transcript

Zoetis' (ZTS) earnings and revenues beat estimates in the third quarter of 2021. The company raised its financial guidance for 2021.

Zoetis' (ZTS) Earnings and Revenues Surpass Estimates in Q3

Zoetis (ZTS) delivered earnings and revenue surprises of 13.64% and 2.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Beats Q3 Earnings and Revenue Estimates

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis reports third quarter 2021 financial results.

Zoetis Announces Third Quarter 2021 Results

Endo International

Moderna

Novavax

Regeneron Pharmaceuticals

Let us take a look at five drug/biotech companies due to release their quarterly results on Nov 4.

Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More

Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Zoetis (ZTS) This Earnings Season?

Vertex Pharmaceuticals

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates

Zoetis is the leader in pharmaceutical drugs, nutrition, and diagnostics for companion animals and livestock.

Zoetis: Expensive But Precision Livestock Farming Division Could Be Game Changer

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #ResearchandDevelopment--Robert J. Polzer, PhD, will succeed current EVP and President of R&D at Zoetis, Dr. Catherine Knupp, DVM, MS.

Zoetis Announces Appointment of Robert J. Polzer, PhD, as President of Research & Development for World Leader in Animal Health

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #dividend--The Board of Directors of Zoetis Inc. has declared a fourth quarter 2021 dividend payable to holders of the company's common stock of $0.25 per share.

Zoetis Declares Fourth Quarter 2021 Dividend

Johnson & Johnson

Here are two stocks to add to your basket of buys this fall.

Got $1,000? 2 Super-Smart Stocks That Could Make You Richer Over the Next Decade

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #earnings--Zoetis Inc. will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 4, 2021.

Zoetis to Host Webcast and Conference Call on Third Quarter 2021 Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis to present at the Jefferies Virtual Pet Care Summit on Thursday, Sept. 16th.

News for Zoetis Stock (ZTS)